Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

First-in-class, cardioprotective drug with potential to transform treatment following myocardial infarction and stenting OSLO, Norway, May 22, 2023 /PRNewswire/ —¬†Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data … Read more